Qure.ai nets six new indications cleared by FDA, taking the chest X-ray crown in the radiology AI race

New Delhi: The US Food and Drug Administration (FDA) has given 510(k) class II clearance of qXR-Detect, the latest computer-assisted detection (CADe) radiography solution from global AI company Qure.ai. It powers the early identification, highlighting and categorizing of key positive findings on plain film chest X-rays to support emergency room (ER) physicians, family medicine practitioners and radiologists.

Chest radiography is the most performed imaging exam today in the US, with 70 million obtained each year in the ER, outpatient department, or part of routine health assessments. This ‘6 in 1’ indication FDA clearance, completes the entire qXR product suite of AI algorithms, covering the breadth of findings encountered on chest X-rays. Findings that can be categorized into six regions of interest are added including – lung; pleura; mediastinum /hila & heart; bone; hardware and others.

“There are more than 100 potential findings on a plain film chest X-ray that AI tools can help detect and assist radiologists with, supporting earlier recognition of abnormalities,” states Professor Amit Gupta, Division Chief of Cardiothoracic Imaging and Modality Director of Diagnostic Radiography at University Hospitals Cleveland Medical Center. “Tools such as qXR-Detect go beyond binary detection alone. In addition to flagging potential abnormalities, the system provides visual localization and explainability, such as through bounding boxes and region-of-interest labels, which helps the interpreting radiologist quickly understand where and why an alert has been generated. When used alongside standard clinical interpretation, chest radiography augmented with AI-based detection and localization can offer a practical frontline support tool for identifying findings such as lung nodules and other abnormalities that may warrant closer attention or further diagnostic workup.”

“These super six indications cleared by the FDA for qXR-Detect establishes Qure.ai as the foremost commercial AI company, with the most comprehensive regulatory clearances for chest X-ray globally,” states Samir Shah, Chief Medical Officer at Qure.ai. “qXR-Detect is also the only chest X-ray CADe device cleared by the FDA with a Predetermined Change Control Plan (PCCP). This will help assure US health system customers access to the most up-to-date version of the algorithm as models and architecture evolves. This new clearance is testimony to the robust FDA regulatory process Qure.ai upholds and an exciting moment for all involved in the quest to create a stage shift in lung cancer.”